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Abstract
Background: Among genitourinary malignancies, bladder cancer (BCa) ranks second in both prevalence and
cause of death. Biomarkers of BCa for diagnosis, prognosis and disease surveillance could potentially help prevent
progression, improve survival rates and reduce health care costs. Among several oncogenic signaling pathways
implicated in BCa progression is that of hepatocyte growth factor (HGF) and its cell surface receptor, Met, now
targeted by 25 experimental anti-cancer agents in human clinical trials. The involvement of this pathway in several
cancers is likely to preclude the use of urinary soluble Met (sMet), which has been correlated with malignancy, for
initial BCa screening. However, its potential utility as an aid to disease surveillance and to identify patients likely to
benefit from HGF/Met-targeted therapies provide the rationale for this preliminary retrospective study comparing
sMet levels between benign conditions and primary BCa, and in BCa cases, between different disease stages.
Methods: Normally voided urine samples were collected from patients with BCa (Total: 183; pTa: 55, pTis: 62,
pT1: 24, pT2: 42) and without BCa (Total: 83) on tissue-procurement protocols at three institutions and sMet was
measured and normalized to urinary creatinine. Normalized sMet values grouped by pathologic stage were compared
using non-parametric tests for correlation and significant difference. ROC analyses were used to derive classification
models for patients with or without BCa and patients with or without muscle-invasive BCa (MIBCa or NMIBCa).
Results: Urinary sMet levels accurately distinguished patients with BCa from those without (p < 0.0001, area under the
curve (AUC): 0.7008) with limited sensitivity (61%) and moderate specificity (76%), and patients with MIBCa (n = 42)
from those with NMIBCa (n = 141; p < 0.0001, AUC: 0.8002) with moderate sensitivity and specificity (76% and 77%,
respectively) and low false negative rate (8%).
Conclusions: Urinary sMet levels distinguish patients with BCa from those without, and patients with or without
MIBCa, suggesting the potential utility of urinary sMet as a BCa biomarker for surveillance following initial treatment.
Further studies are warranted to determine its potential value for prognosis in advanced disease, predicting treatment
response, or identifying patients likely to benefit from Met-targeted therapies.
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Background
In 2013, 72,570 new cases of bladder cancer (BCa) and
15,210 bladder cancer-related deaths were estimated in
the U.S. alone [1]. In approximately 70% of newly diag-
nosed bladder cancer cases, disease is confined to the
mucosa, but requires long term monitoring by cystos-
copy to detect frequent recurrences. The remaining 30%
of new cases present at a more advanced stage, with
muscle-invasion, locoregional nodal involvement or dis-
tant metastases. About half of those individuals with
muscle-invasive bladder cancer fail surgical or chemora-
diation definitive therapy within 5 years and succumb to
the disease [1,2]. The 5- and 10-year survival rates for
patients with lymph node involvement are 31 and 23%,
respectively [2]. Combination platinum-based chemo-
therapy, the standard or care for patients with metastatic
disease, provides a median survival of only 15 months
and a 5-year survival rate of less than 15% [3]. BCa has
the highest costs per patient in the U.S. compared to all
other cancers, reflecting disease prevalence as well as
costs of long term monitoring [4]. These circumstances
underscore the urgent need for finding novel disease
biomarkers and treatments.
The cell surface receptor tyrosine kinase for hepato-
cyte growth factor (HGF), known as Met, is widely
present in cells of epithelial origin. HGF/Met signaling is
required for normal development and adult homeostasis
but is also frequently implicated in cancer, contributing
to tumor invasiveness and metastasis [5]. Evidence of
HGF/Met pathway involvement in BCa has been found
in model systems [6-8] and in vivo [9-11]. In a prior
study we found that proteolytic shedding of soluble Met
(sMet) ectodomain from cells increased with transform-
ation and correlated with malignancy, and we devel-
oped a high-throughput, two-site immunoassay for
Met ectodomain detection with four-log linearity and
attomole sensitivity [12]. This assay is ideally suited to
low protein samples such as urine, where, in constant
contact with the urothelium, even small changes in
sMet might be detected. The goal of the retrospective
study described here was to obtain an initial assess-
ment of urinary sMet level as a potential biomarker of
urothelial carcinoma of the bladder using normally
voided, tissue banked specimens collected at urology
departments of three institutions. The findings that
urinary sMet levels were significantly higher in BCa
patients than in individuals with no evidence of cancer,
higher in muscle-invasive than in non-invasive cancer,
and higher in more malignant pathologic stages, sug-
gest that follow-up prospective clinical studies to in-
vestigate its potential utility in disease prognosis, as an
aid to disease surveillance, and to identify patients
likely to benefit from HGF/Met-targeted therapies, are
warranted.
Methods
Patients and Samples
From 2005 to 2012, normally voided urine samples were
collected from patients enrolled in IRB approved tissue
procurement protocols at the National Cancer Institute,
the Brady Urological Institute of The Johns Hopkins
University School of Medicine and Washington University
in St. Louis, by informed consent prior to cystoscopy,
transurethral resection or cystectomy. sMet values were
normalized to urinary creatinine values obtained by
standard clinical tests on the same sample. Only pa-
tients with a pathology confirmation of UC of the blad-
der were included in the final analysis; reports were
reviewed as they appeared in electronic medical re-
cords. Patients with other known cancers in addition
to bladder cancer were excluded. The control group
was composed of patients with benign bladder path-
ology and not known to have any other malignancy.
Two-site electrochemiluminescent sMet immunoassay
Normally voided urine samples were stored at −80°C
prior to analysis. Thawed samples were processed by
centrifugation, ultrafiltration and pH adjustment to 7.0
prior to sMet quantitation as described previously [12].
Briefly, streptavidin-coated 96-well plates were blocked,
washed with PBS and coated with a biotin-tagged, affinity-
purified human Met ectodomain-specific capture antibody
(BAF358, R&D Systems). Wells were washed again before
adding sample or sMet standard (358-MT, R&D Systems)
for 1 h with shaking. After washing with PBS, detection
antibody (AF276, R&D Systems) labeled with MSD-Sulfo-
Tag (Meso Scale Discovery) was added for 1 h with shaking.
Wells were washed with PBS before adding read buffer and
plates were read in a MSD Sector Imager 2400. Assays were
performed blinded to study endpoint.
Statistical analysis
Statistical analyses were performed using JMP (SAS
Institute Inc.), Excel (Microsoft Inc.) and Prism (GraphPad
Software Inc.). Wilcoxon, Mann Whitney and Kruskal-
Wallis tests, in conjunction with the Bonferroni mul-
tiple test correction, were used to determine statistical
differences between groups. Assuming a single test
significance level of 0.05, the Bonferrroni multiple test
correction for 13 combined tests (10 as shown in
Table 1 plus control vs. BCa and NMIBCa vs. MIBCa,
and control vs tumor grade, high or low) gives an
adjusted significance level of 0.0038; this value was
used in denoting significant differences in the text and
Figure 1A,B and C. Receiver Operating Curves (ROC)
were calculated and Area Under the Curve (AUC) de-
termined using JMP. Cutoff values determined using a
45° line drawn tangential to the ROC curve (Figure 1D
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and E) were used to develop specificity, sensitivity and
prediction values.
Results
Urine samples for sMet analysis were obtained from 183
patients with BCa (pTa: 55, pTis: 62, pT1: 24, pT2: 42)
and 83 patients without evidence of bladder cancer (con-
trol). Median urine sMet/creatinine values (ng/mg) were
significantly different between control and all BCa
patients (Figure 1A; p < 0.0001) and between controls
and BCa patients with disease stage of Ta, T1 or T2
(Figure 1B). Mann–Whitney p values for differences
among controls and each pathologic stage are listed in
Table 1. With the exception of Tis, the results indicate
progressively increasing sMet/creatinine values be-
tween stages. Although samples were obtained from
patients with stage T3 or T4a disease, many of these
patients had undergone radical cystectomy, and differ-
ences in sMet levels observed between these and nor-
mally voided samples suggested that an independent
study to distinguish the effects of cystectomy from
those of BCa on sMet level was needed; therefore only
patients with intact bladders and BCa stage T2 or
lower were included in this study. BCG treatment was
also observed to transiently elevate urinary sMet levels;
only samples from patients that had received BCG
Table 1 Mann–Whitney p values for difference
comparisons in urinary median sMet/creatinine levels
among controls and BCa stages
Control (n = 83) Tis (n = 62) Ta (n = 55) T1 (n = 24)
Tis 0.2213
Ta 0.0002 0.0367
T1 0.0003 0.0110 0.2474
T2 (n = 42) <0.0001 <0.0001 <0.0001 0.0127
Figure 1 Comparison of urinary sMet levels among BCa patients and controls. A. Box and whisker plot of urine sMet/creatinine values (ng
sMet/mg creatinine) for control patients with no evidence of BCa (n = 83) and patients with pathology proven BCa (n = 183). Red asterisk
indicates significant difference in median value from control (Mann–Whitney test with Bonferroni multiple test correction). B. Box and whisker
plots of urine sMet/creatinine values (ng sMet/mg creatinine) for control patients with no evidence of BCa and patients with BCa subdivided by
pathologic stage. N for each group are listed in Table 1. Red asterisks indicate significant difference in median value from control; black asterisks
indicate significant differences among medians as indicated by brackets (Mann–Whitney test with Bonferroni multiple test correction). C. Box and
whisker plot of urine sMet/creatinine values (ng sMet/mg creatinine) for control patients with no evidence of BCa (n = 83), patients with NMIBCa
(n = 141) or with MIBCa (n = 42). Red asterisks indicate significant difference in median value from control; black asterisk indicates significant
differences among medians as indicated by brackets (Mann–Whitney test with Bonferroni multiple test correction). D. ROC curve of urine sMet/
creatinine values (ng sMet/mg creatinine) for control patients with no evidence of BCa (n = 83) and patients with pathology proven BCa (n = 183).
E. ROC curve of urine sMet/creatinine values (ng sMet/mg creatinine) for patients with NMIBCa (n = 141) or with MIBCa (n = 42). Criterion values
balancing sensitivity and specificity are indicated by the gray lines tangent to the ROC curves.
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therapy more than one month prior were included in
the final analysis.
Consistent with the known role of HGF/Met signaling
in tumor invasiveness and the correlation between Met
shedding and malignancy found previously, the median
urinary sMet/creatinine value of patients with non-muscle
invasive BCa (NMIBCa; n = 141) was significantly lower
than that of patients with muscle-invasive BCa (MIBCa; n
= 42; p < 0.0001; Figure 1C). Both BCa groups were signifi-
cantly higher than control (control vs NMIBCa p = 0.0004;
control vs MIBCa p < 0.0001; Figure 1C). Significant dif-
ferences in median urinary sMet levels were also found
between control (n = 83) and low grade tumor groups
(n = 25; p = 0.0001) and between control and high grade
tumor groups (n = 59; p = 0.0013), but not between low
grade and high grade tumor groups. Comparison of
median sMet levels in subjects with no cytologic atypia to
those with any degree of atypia (atypia, suspicious for
cancer or positive for cancer) showed a trend towards
statistical significance (p = 0.0087) but did not meet the
significance threshold adjustment for 14 correlative tests
(p < 0.0036); these results were further limited as only 48/
183 (26.2%) of subjects had cytologic analysis performed.
ROC analysis of control vs BCa groups (Figure 1D)
yielded an AUC of 0.7008. A criterion value of > 0.920 to
classify patients as benign or having BCa yielded 61.2%
sensitivity and 75.9% specificity (Table 2). Similar analysis
of NMIBCa vs MIBCa groups (Figure 1E) yielded an AUC
of 0.8002, and a criterion value of > 1.650 yielded 76.2%
sensitivity and 77.3% specificity (Table 2).
Discussion
There are currently over 500,000 cases of bladder cancer
in the U.S., and this disease also has the highest cost per
patient across all types of cancer [4] due to in large part
to continuous invasive cystoscopic surveillance of non-
muscle invasive disease. Non muscle-invasive tumors have
a high rate of recurrence (up to 70%) and more than 15%
progress to higher stages, usually muscle-invasive disease.
The American Urological Association recommends cysto-
scopic tumor surveillance every 3–6 months for 3 years
and at least yearly thereafter [13], and the US National
Comprehensive Cancer Network has made similar recom-
mendations [14]. Surveillance with cystoscopy, and trans-
urethral resection of a bladder lesion (TURBT) when
necessary, carries risk of infection and trauma to the lower
urinary tract, and these procedures also represent the
most dollars allocated for the treatment of bladder cancer
[15,16]. Furthermore, a substantial fraction of patients are
managed with an intensity of follow-up and treatment that
does not correlate with improved cancer-specific survival
or avoidance of a major intervention; in fact, patients who
received more intensive treatment were more likely to
undergo subsequent radical cystectomy [17,18]. Thus, a
low cost, non-invasive method of bladder cancer detection
and surveillance that could diminish the number of proce-
dures being performed would significantly benefit patients
and health care systems.
Cytology is currently the most widely used test for the
detection of BCa [19]. While cytology is very specific
(96%), its usefulness is limited by low sensitivity (44%),
particularly for low-grade disease [20]. The interpret-
ation of cytological specimens varies depending on how
the specimens were acquired (i.e. via voiding, cystoscopy,
ureteral brushings or urethral catheterization), and re-
quires a highly trained pathologist, making the test com-
pletely operator dependent; inter-observer agreement
has been reported to be highly variable [21]. All current
U.S. FDA-approved non-invasive tests for the detection
of BCa have higher sensitivities than cytology (FISH: 76%,
NMP22: 68%, ImmunoCyt: 84%), but lower specificity
(FISH: 85%, NMP22: 79%, ImmunoCyt: 75%) [20,22]. The
estimated sensitivity of the sMet assay for detection of
BCa (61%) is lower than the FISH, NMP22 or ImmunoCyt
tests. In addition to this limitation, the widespread in-
volvement of HGF/Met signaling in human cancers, par-
ticularly those with direct exposure to the urinary tract
such as renal cell carcinoma and prostate cancer, raises
the likely possibility that other malignancies may be asso-
ciated with increased urinary sMet [12]. Thus, we do not
foresee urinary sMet measurement alone fulfilling the role
of an initial BCa screen. It is noteworthy that the multiwell
electrochemiluminescent platform used here is well suited
to multiplexing sMet measurement with other tests (up to
6 at present) performed simultaneously on the same sam-
ple. A multiplexed urine test that met criteria for reliable
BCa screening would complement existing diagnostic
methods and is widely sought.
More immediately, several attributes indicate the suit-
ability of urinary sMet measurement for BCa surveil-
lance: a very high degree of precision; good specificity
(76%); low false positive rate (PPV 85%); good sensitivity
to MIBCa (76%) and a very low false negative rate (NPV
92%). Accuracy is based on external reference standards
Table 2 Sensitivity, specificity, positive (PPV) and negative predictive values (NPV), and Area Under the Curves (AUCs)
derived from ROC analyses of sMet/creatinine value comparisons
Comparison Criterion Sensitivity Specificity PPV NPV AUC
Control vs BCa > 0.920 0.6120 0.7590 0.8485 0.4701 0.7008
NMIBCa vs MIBCa > 1.650 0.7619 0.7730 0.5000 0.9160 0.8002
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(for sMet and creatinine) that enable longitudinal com-
parisons between individuals or groups. A reliable bio-
marker for surveillance would compliment cystoscopy
and TURBT and could potentially reduce the frequency of
these invasive procedures and their associated costs [23].
The sMet immunoassay is robust, fast, high throughput,
and easily automated; the combined materials and labor
cost of the two-site immunoassay used in our study was
less than $30 per sample. These features, together with
the use of commercially available reagents and an estab-
lished assay platform, indicate simple, low cost implemen-
tation by existing clinical laboratories.
The development of prognostic biomarkers and pre-
dictive biomarkers for identifying patients most likely to
benefit from targeted agents are also active areas of re-
search in urothelial carcinoma. Met abundance has been
associated with a worse prognosis for many tumor types
and may be associated with more aggressive urothelial
tumors [24]; in a limited survey of human urothelial
cancer-derived cell lines, we found that Met content
correlated directly with disease grade and metastatic
potential in mice [25]. The potential prognostic value of
urinary sMet as a surrogate of tumor Met expression in
BCa patients with an intact bladder is currently under
investigation.
Finally, significant correlations between tumor Met con-
tent and treatment response have been reported for HGF/
Met pathway inhibitors in advanced gastric and lung can-
cers [5,26-28]. Although these studies suggest that tumor
Met levels may predict response to treatment, they also
bring to light potential obstacles to obtaining this informa-
tion for a large patient population, e.g. limited availability
of primary tumor samples, and safety and/or feasibility
issues in advanced disease where metastases may be in-
accessible for biopsy. We are currently investigating the
clinical value of urinary sMet as a prognostic and predict-
ive biomarker in patients with advanced urothelial cancer
undergoing Met targeted therapy [26]; NCT01688999.
Conclusions
Urinary sMet levels distinguish patients with BCa from
those without, and patients with or without MIBCa. Be-
cause elevated urinary sMet may be associated with malig-
nancies other than BCa, sMet measurement alone is not
appropriate as a primary BCa screen. However, urinary
sMet may have utility as a BCa biomarker for surveillance
following initial diagnosis and treatment. Further clinical
studies are warranted to determine the potential utility of
urinary sMet for prognosis in more advanced disease,
predicting treatment response, and for identifying patients
likely to benefit from Met-targeted therapies.
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